Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance pembrolizumab after chemoradiotherapy in unresectable stage III NSCLC (MP-LALC)
2016-001252-22Phase 2Active
- Sponsor
- University of Turin, Department of Oncology
- Start
- Nov 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by University of Turin, Department of Oncology. Primary endpoint: overall survival. Started Nov 2020; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2016-001252-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001252-22.